X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs STRIDES SHASUN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD STRIDES SHASUN LTD ORCHID PHARMA LTD/
STRIDES SHASUN LTD
 
P/E (TTM) x -0.5 13.3 - View Chart
P/BV x 0.4 1.5 23.4% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   STRIDES SHASUN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
STRIDES SHASUN LTD
Mar-17
ORCHID PHARMA LTD/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1941,275 15.2%   
Low Rs35918 3.8%   
Sales per share (Unadj.) Rs276.5389.6 71.0%  
Earnings per share (Unadj.) Rs-79.228.0 -283.2%  
Cash flow per share (Unadj.) Rs-43.548.9 -88.9%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9303.1 17.8%  
Shares outstanding (eoy) m70.4589.42 78.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.8 14.7%   
Avg P/E ratio x-1.439.2 -3.7%  
P/CF ratio (eoy) x-2.622.4 -11.8%  
Price / Book Value ratio x2.13.6 58.7%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m8,06798,036 8.2%   
No. of employees `0002.85.8 48.3%   
Total wages/salary Rs m2,5275,881 43.0%   
Avg. sales/employee Rs Th6,956.16,005.9 115.8%   
Avg. wages/employee Rs Th902.51,014.0 89.0%   
Avg. net profit/employee Rs Th-1,993.0431.2 -462.2%   
INCOME DATA
Net Sales Rs m19,47734,834 55.9%  
Other income Rs m4071,686 24.2%   
Total revenues Rs m19,88436,520 54.4%   
Gross profit Rs m1,1036,428 17.2%  
Depreciation Rs m2,5191,872 134.6%   
Interest Rs m5,2272,269 230.3%   
Profit before tax Rs m-6,2363,973 -157.0%   
Minority Interest Rs m200-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m511-1,006 -50.8%   
Tax Rs m-125470 -26.6%   
Profit after tax Rs m-5,5802,501 -223.1%  
Gross profit margin %5.718.5 30.7%  
Effective tax rate %2.011.8 17.0%   
Net profit margin %-28.77.2 -399.1%  
BALANCE SHEET DATA
Current assets Rs m11,01438,165 28.9%   
Current liabilities Rs m32,06030,402 105.5%   
Net working cap to sales %-108.122.3 -484.9%  
Current ratio x0.31.3 27.4%  
Inventory Days Days9577 122.7%  
Debtors Days Days34104 32.1%  
Net fixed assets Rs m29,44037,639 78.2%   
Share capital Rs m705894 78.8%   
"Free" reserves Rs m2,04326,210 7.8%   
Net worth Rs m3,80027,105 14.0%   
Long term debt Rs m9,01816,377 55.1%   
Total assets Rs m46,51081,168 57.3%  
Interest coverage x-0.22.8 -7.0%   
Debt to equity ratio x2.40.6 392.8%  
Sales to assets ratio x0.40.4 97.6%   
Return on assets %-0.85.9 -12.9%  
Return on equity %-146.99.2 -1,591.6%  
Return on capital %-3.712.1 -31.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51313,465 55.8%   
Fx outflow Rs m5,6494,076 138.6%   
Net fx Rs m1,8659,389 19.9%   
CASH FLOW
From Operations Rs m1,6822,881 58.4%  
From Investments Rs m-9,860-7,051 139.8%  
From Financial Activity Rs m6,6443,382 196.4%  
Net Cashflow Rs m-1,535-788 194.9%  

Share Holding

Indian Promoters % 32.3 27.7 116.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 37.8 12.2%  
FIIs % 3.3 8.6 38.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 25.9 213.5%  
Shareholders   84,811 56,241 150.8%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 21, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS